CorVel (NASDAQ:CRVL) Director R Judd Jessup Sells 1,262 Shares

CorVel Corp. (NASDAQ:CRVL) Director R Judd Jessup sold 1,262 shares of the firm’s stock in a transaction that occurred on Thursday, August 27th. The shares were sold at an average price of $70.64, for a total transaction of $89,147.68. Following the transaction, the director directly owned 115,821 shares in the company, valued at approximately $8,181,595.44. The trade was a 1.08% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website.

R Judd Jessup also recently made the following trade(s):

• On Wednesday, August 26th, R Judd Jessup sold 1,562 shares of CorVel stock. The stock was sold at an average price of $70.71, for a total transaction of $110,449.02.

CorVel Trading Down 0.3%

CRVL stock opened at $69.24 on Friday. CorVel Corp. has a 1 year low of $44.83 and a 1 year high of $93.45. The company has a fifty day simple moving average of $63.41 and a 200 day simple moving average of $58.22. The firm has a market cap of $3.53 billion, a PE ratio of 30.77 and a beta of 0.98.

CorVel (NASDAQ:CRVL) last issued its quarterly earnings data on Tuesday, August 4th. The business services provider reported $0.63 earnings per share (EPS) for the quarter. The firm had revenue of $259.93 million during the quarter. CorVel had a net margin of 11.72% and a return on equity of 29.92%.

Institutional Investors Weigh In On CorVel

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Royal Bank of Canada lifted its stake in shares of CorVel by 12.5% in the first quarter. Royal Bank of Canada now owns 51,261 shares of the business services provider’s stock valued at $5,739,000 after buying an additional 5,703 shares during the period. AQR Capital Management LLC grew its position in CorVel by 4.0% during the first quarter. AQR Capital Management LLC now owns 26,468 shares of the business services provider’s stock worth $2,964,000 after buying an additional 1,013 shares in the last quarter. Integrated Wealth Concepts LLC raised its holdings in CorVel by 11.4% in the 1st quarter. Integrated Wealth Concepts LLC now owns 3,800 shares of the business services provider’s stock valued at $425,000 after acquiring an additional 389 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in shares of CorVel by 4.6% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 15,846 shares of the business services provider’s stock worth $1,774,000 after acquiring an additional 702 shares during the period. Finally, Millennium Management LLC lifted its position in shares of CorVel by 127.4% in the 1st quarter. Millennium Management LLC now owns 48,182 shares of the business services provider’s stock worth $5,395,000 after acquiring an additional 26,990 shares during the period. Institutional investors and hedge funds own 51.36% of the company’s stock.

Analyst Ratings Changes

Several analysts have recently issued reports on CRVL shares. Wall Street Zen upgraded CorVel from a “hold” rating to a “buy” rating in a research note on Saturday, May 30th. Weiss Ratings raised CorVel from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Thursday, July 16th. One equities research analyst has rated the stock with a Hold rating, Based on data from MarketBeat.com, the company has a consensus rating of “Hold”.

About CorVel

CorVel Corporation (NASDAQ: CRVL) is a technology-driven provider of workers’ compensation, liability, and specialty risk management solutions. The company develops and deploys software and data analytics tools to streamline claims administration, medical cost containment, prescription drug management, and provider network access. CorVel’s integrated platform connects employers, insurers, healthcare providers, and injured workers, aiming to improve outcomes and control costs through process automation and real-time decision support.

The company’s product suite includes claims lifecycle management, bill review and negotiation, virtual care and telehealth services, pharmacy benefit management, and independent medical examinations (IMEs).